Paton Carol, Crawford Michael J, Bhatti Sumera F, Patel Maxine X, Barnes Thomas R E
Oxleas NHS Foundation Trust, Pinewood House, Pinewood Place, Dartford, Kent DA5 7WG, England
J Clin Psychiatry. 2015 Apr;76(4):e512-8. doi: 10.4088/JCP.14m09228.
Guideline recommendations for the pharmacologic treatment of personality disorder lack consensus, particularly for emotionally unstable personality disorder (EUPD), and there is limited information on current prescribing practice in the United Kingdom.
To characterize the nature and quality of current prescribing practice for personality disorder across the United Kingdom, as part of a quality improvement program.
A cross-sectional survey of self-selected psychiatric services providing care for adults with personality disorder (ICD-10 criteria) was conducted. Data were collected during May 2012.
Of 2,600 patients with a diagnosis of personality disorder, more than two-thirds (68%) had a diagnosis of EUPD. Almost all (92%) patients in the EUPD subgroup were prescribed psychotropic medication, most commonly an antidepressant or antipsychotic, principally for symptoms and behaviors that characterize EUPD, particularly affective dysregulation. Prescribing patterns were similar between those who had a diagnosed comorbid mental illness and those who had EUPD alone, but the latter group was less likely to have had their medication reviewed over the previous year, particularly with respect to tolerability (53% vs 43%).
The use of psychotropic medication in EUPD in the United Kingdom is largely outside the licensed indications. Whether the treatment target is identified as intrinsic symptoms of EUPD or comorbid mental illness may depend on the diagnostic threshold of individual clinicians. Compared with prescribing for EUPD where there is judged to be a comorbid mental illness, the use of off-label medication for EUPD alone is less systematically reviewed and monitored, so opportunities for learning may be lost. Treatment may be continued long term by default.
关于人格障碍药物治疗的指南建议缺乏共识,尤其是针对情绪不稳定人格障碍(EUPD),而且关于英国目前的处方实践信息有限。
作为质量改进计划的一部分,描述英国目前人格障碍处方实践的性质和质量。
对自行选择的为符合人格障碍(国际疾病分类第10版标准)的成年人提供护理的精神科服务进行横断面调查。数据于2012年5月收集。
在2600名被诊断为人格障碍的患者中,超过三分之二(68%)被诊断为EUPD。EUPD亚组中几乎所有(92%)患者都被开具了精神药物,最常见的是抗抑郁药或抗精神病药,主要用于治疗EUPD特有的症状和行为,尤其是情感失调。有共病精神疾病诊断的患者和仅患有EUPD的患者的处方模式相似,但后一组在过去一年接受药物复查的可能性较小,尤其是在耐受性方面(53%对43%)。
在英国,EUPD中精神药物的使用大多超出了许可适应症范围。治疗目标被确定为EUPD的内在症状还是共病精神疾病,可能取决于个体临床医生的诊断阈值。与针对被判定有共病精神疾病的EUPD患者的处方相比,单独针对EUPD使用非标签药物的情况较少得到系统的复查和监测,因此可能会失去学习机会。治疗可能会默认长期持续下去。